Nutricircle Limited announced it will close its trading window for directors, officers, and designated employees, effective April 1, 2026. This standard measure is in place to prevent potential insider trading ahead of the company's audited financial results for the fiscal year ending March 31, 2026.
The closure aligns with Securities and Exchange Board of India (SEBI) regulations designed to ensure fair market practices and transparency.
Nutricircle anticipates its board of directors will approve the audited financial results by May 30, 2026. The trading window is set to reopen 48 hours after the official announcement of these results.
This step aims to ensure all investors receive important company information simultaneously, highlighting Nutricircle's commitment to corporate governance. Similar trading window closure norms are followed by peers in the Indian pharmaceutical sector, including Aristo Pharma India Limited and Lasa Supergenerics Limited.
